Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies
CONCLUSIONS: In this pooled data analysis from 3 studies in pediatric patients with HoFH, evolocumab was well tolerated, with no new safety signals reported. These safety findings are consistent with findings from previous studies of evolocumab. Patients showed marked variability in LDL-C reduction. Results from this pooled analysis support guidelines suggesting a trial of PCSK9 inhibitor therapy regardless of estimated residual LDLR function.REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01624142, NCT03403374, and NCT02624869.PMID:38545781 | DOI:10.1161/ATVBAHA.123.320268 (Source: Arteriosclerosi...
Source: Arteriosclerosis, Thrombosis and Vascular Biology - March 28, 2024 Category: Cardiology Authors: Frederick J Raal Robert A Hegele Andrea Ruzza J Antonio G L ópez Ajay K Bhatia Johnny Wu Huei Wang Daniel Gaudet Albert Wiegman Jian Wang Raul D Santos Source Type: research
Exploring a New Pathophysiological Association in Acne Vulgaris and Metabolic Syndrome: The Role of Biogenic Amines and Glutathione Peroxidase
Conclusions: The complex connection between GTPx and catecholamines in MetS suggests a significant role of these factors in the pathogenesis of acne associated with this condition, opening new perspectives in the research and treatment of acne in the context of MetS.PMID:38541239 | DOI:10.3390/medicina60030513 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - March 28, 2024 Category: Universities & Medical Training Authors: Alexa Florina Bungau Delia Mirela Tit Manuela Stoicescu Lavinia-Cristina Moleriu Mariana Muresan Ada Radu Mihaela Cristina Brisc Timea Claudia Ghitea Source Type: research
Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies
CONCLUSIONS: In this pooled data analysis from 3 studies in pediatric patients with HoFH, evolocumab was well tolerated, with no new safety signals reported. These safety findings are consistent with findings from previous studies of evolocumab. Patients showed marked variability in LDL-C reduction. Results from this pooled analysis support guidelines suggesting a trial of PCSK9 inhibitor therapy regardless of estimated residual LDLR function.REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01624142, NCT03403374, and NCT02624869.PMID:38545781 | DOI:10.1161/ATVBAHA.123.320268 (Source: Arteriosclerosi...
Source: Arteriosclerosis, Thrombosis and Vascular Biology - March 28, 2024 Category: Cardiology Authors: Frederick J Raal Robert A Hegele Andrea Ruzza J Antonio G L ópez Ajay K Bhatia Johnny Wu Huei Wang Daniel Gaudet Albert Wiegman Jian Wang Raul D Santos Source Type: research
